Control of death receptor ligand activity by posttranslational modifications

Cellular and Molecular Life Sciences

Volumn 67, Issue 10, 2010, Pages 1631-1642

  Weinlich, R ^a,b,d   Brunner, T ^c   Amarante Mendes, G P ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Instituto Nacional de Ciencia e Tecnologia   (Brazil)

^c UNIVERSITY OF BERN   (Switzerland)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

ADAM; Degranulation; FasL; Lysosomes; Metalloprotease; Rafts; Shedding; TNF; TRAIL

Indexed keywords

DEATH RECEPTOR; FAS LIGAND; LIGAND; PROTEINASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; CELL ACTIVATION; CELL MEMBRANE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; DEGRANULATION; HUMAN; INFLAMMATION; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; REVIEW; TRANSCRIPTION REGULATION; ANIMAL; METABOLISM; PROTEIN TRANSPORT;

ANIMALS; CELL MEMBRANE; HUMANS; LIGANDS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; RECEPTORS, DEATH DOMAIN;

EID: 77951930989     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-010-0289-7     Document Type: Review

References (150)

1. A Ashkenazi VM Dixit 1998 Death receptors: signaling and modulation Science 281 1305 1308 9721089 10.1126/science.281.5381.1305 1:CAS:528: DyaK1cXlvVegsL0%3D
2. S Nagata 1997 Apoptosis by death factor Cell 88 355 365 9039262 10.1016/S0092-8674(00)81874-7 1:CAS:528:DyaK2sXhtFahtbg%3D (Pubitemid 27131377)
3. HJ Gruss SK Dower 1995 Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas Blood 85 3378 3404 7780126 1:CAS:528:DyaK2MXmtlOmtrs%3D
4. SJ Baker EP Reddy 1998 Modulation of life and death by the TNF receptor superfamily Oncogene 17 3261 3270 9916988 10.1038/sj.onc.1202568
5. HJ Gruss 1996 Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily Int J Clin Lab Res 26 143 159 8905447 10.1007/BF02592977 1:CAS:528:DyaK28XmslCjs70%3D
6. P Schneider N Holler JL Bodmer M Hahne K Frei A Fontana J Tschopp 1998 Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity J Exp Med 187 1205 1213 9547332 10.1084/jem.187.8.1205 1:CAS:528: DyaK1cXis1Cru7o%3D (Pubitemid 28189110)
7. E Bonfoco PM Stuart T Brunner T Lin TS Griffith Y Gao H Nakajima PA Henkart TA Ferguson DR Green 1998 Inducible nonlymphoid expression of Fas ligand is responsible for superantigen-induced peripheral deletion of T cells Immunity 9 711 720 9846492 10.1016/S1074-7613(00)80668-8 1:CAS:528:DyaK1cXnvFWrsrg%3D
8. LE French M Hahne I Viard G Radlgruber R Zanone K Becker C Muller J Tschopp 1996 Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover J Cell Biol 133 335 343 8609166 10.1083/jcb.133.2.335 1:CAS:528:DyaK28Xitlyms7g%3D (Pubitemid 26132532)
9. T Brunner NJ Yoo D LaFace CF Ware DR Green 1996 Activation-induced cell death in murine T cell hybridomas. Differential regulation of Fas (CD95) versus Fas ligand expression by cyclosporin A and FK506 Int Immunol 8 1017 1026 8757947 10.1093/intimm/8.7.1017 1:CAS:528:DyaK28XksFCltLo%3D (Pubitemid 26235705)
10. DA Hildeman Y Zhu TC Mitchell J Kappler P Marrack 2002 Molecular mechanisms of activated T cell death in vivo Curr Opin Immunol 14 354 359 11973134 10.1016/S0952-7915(02)00335-7 1:CAS:528:DC%2BD38XjtVeitL8%3D (Pubitemid 34327978)
11. TS Griffith X Yu JM Herndon DR Green TA Ferguson 1996 CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance Immunity 5 7 16 8758890 10.1016/S1074-7613(00)80305-2 1:CAS:528:DyaK28Xks1Omtbw%3D (Pubitemid 26254781)
12. M Maksimow TS Soderstrom S Jalkanen JE Eriksson A Hanninen 2006 Fas costimulation of naive CD4 T cells is controlled by NF-kappaB signaling and caspase activity J Leukoc Biol 79 369 377 16330535 10.1189/jlb.0505238 1:CAS:528:DC%2BD28Xht12rtbY%3D (Pubitemid 44831169)
13. B Beutler A Cerami 1989 The biology of cachectin/TNF: a primary mediator of the host response Annu Rev Immunol 7 625 655 2540776 1:CAS:528: DyaL1MXit12ltro%3D
14. T Decker ML Lohmann-Matthes GE Gifford 1987 Cell-associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages J Immunol 138 957 962 3492537 1:CAS:528:DyaL2sXhtFOrtrY%3D
15. SR Wiley K Schooley PJ Smolak WS Din CP Huang JK Nicholl GR Sutherland TD Smith C Rauch CA Smith RG Goodwin 1995 Identification and characterization of a new member of the TNF family that induces apoptosis Immunity 3 673 682 8777713 10.1016/1074-7613(95)90057-8 1:CAS:528:DyaK28XhtF2iug%3D%3D (Pubitemid 26091143)
16. C Zhang J Zhang J Niu Z Zhou J Zhang Z Tian 2008 Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D Hum Immunol 69 490 500 18619507 10.1016/j.humimm.2008.06.004 1:CAS:528: DC%2BD1cXpvFGgtLg%3D
17. N Kayagaki N Yamaguchi M Nakayama K Takeda H Akiba H Tsutsui H Okamura K Nakanishi K Okumura H Yagita 1999 Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells J Immunol 163 1906 1913 10438925 1:CAS:528:DyaK1MXltFahu7Y%3D
18. N Kayagaki N Yamaguchi M Nakayama H Eto K Okumura H Yagita 1999 Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs J Exp Med 189 1451 1460 10224285 10.1084/jem.189.9.1451 1:CAS:528:DyaK1MXivFGrsr8%3D (Pubitemid 29227531)
19. O Halaas R Vik A Ashkenazi T Espevik 2000 Lipopolysaccharide induces expression of APO2 ligand/TRAIL in human monocytes and macrophages Scand J Immunol 51 244 250 10736093 10.1046/j.1365-3083.2000.00671.x 1:CAS:528:DC%2BD3cXit1Sisbo%3D (Pubitemid 30151507)
20. K Song Y Chen R Goke A Wilmen C Seidel A Goke B Hilliard Y Chen 2000 Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression J Exp Med 191 1095 1104 10748228 10.1084/jem.191.7.1095 1:CAS:528:DC%2BD3cXit1ygtbc%3D (Pubitemid 30207673)
21. P Secchiero G Zauli 2008 Tumor-necrosis-factor-related apoptosis-inducing ligand and the regulation of hematopoiesis Curr Opin Hematol 15 42 48 18043245 10.1097/MOH.0b013e3282f15fa6 1:CAS:528:DC%2BD1cXnvFWlsg%3D%3D (Pubitemid 350191027)
22. E Ishikawa M Nakazawa M Yoshinari M Minami 2005 Role of tumor necrosis factor-related apoptosis-inducing ligand in immune response to influenza virus infection in mice J Virol 79 7658 7663 15919918 10.1128/JVI.79.12.7658-7663.2005 1:CAS:528:DC%2BD2MXkvFCms7Y%3D (Pubitemid 40756799)
23. R Koschny H Walczak TM Ganten 2007 The promise of TRAIL-potential and risks of a novel anticancer therapy J Mol Med 85 923 935 17437073 10.1007/s00109-007-0194-1 1:CAS:528:DC%2BD2sXptFehtLc%3D (Pubitemid 47282789)
24. Koschny R, Holland H, Sykora J, Erdal H, Krupp W, Bauer M, Bockmuehl U, Ahnert P, Meixensberger J, Stremmel W, Walczak H, Ganten TM (2009) Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis. J Neurooncol, (in press). doi: 10.1007/s11060-009-0010-6
25. V Syed K Mukherjee S Godoy-Tundidor SM Ho 2007 Progesterone induces apoptosis in TRAIL-resistant ovarian cancer cells by circumventing c-FLIPL overexpression J Cell Biochem 102 442 452 17393432 10.1002/jcb.21304 1:CAS:528:DC%2BD2sXhtFKjtLfN (Pubitemid 47519417)
26. H Walczak RE Miller K Ariail B Gliniak TS Griffith M Kubin W Chin J Jones A Woodward T Le C Smith P Smolak RG Goodwin CT Rauch JC Schuh DH Lynch 1999 Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo Nat Med 5 157 163 9930862 10.1038/5517 1:CAS:528:DyaK1MXntlSrug%3D%3D (Pubitemid 29068521)
27. TM Ganten R Koschny J Sykora H Schulze-Bergkamen P Buchler TL Haas MB Schader A Untergasser W Stremmel H Walczak 2006 Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs Clin Cancer Res 12 2640 2646 16638878 10.1158/1078-0432.CCR-05-2635 1:CAS:528:DC%2BD28XjvVaksrc%3D
28. NK Sah A Munshi JF Kurland TJ McDonnell B Su RE Meyn 2003 Translation inhibitors sensitize prostate cancer cells to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by activating c-Jun N-terminal kinase J Biol Chem 278 20593 20602 12663665 10.1074/jbc.M211010200 1:CAS:528:DC%2BD3sXkt1Wjurc%3D (Pubitemid 36806357)
29. I Verbrugge E de Vries SW Tait EH Wissink H Walczak M Verheij J Borst 2008 Ionizing radiation modulates the TRAIL death-inducing signaling complex, allowing bypass of the mitochondrial apoptosis pathway Oncogene 27 574 584 17684487 10.1038/sj.onc.1210696 1:CAS:528:DC%2BD1cXhtVKrurY%3D (Pubitemid 351158906)
30. EH Wissink I Verbrugge SR Vink MB Schader U Schaefer H Walczak J Borst M Verheij 2006 TRAIL enhances efficacy of radiotherapy in a p53 mutant, Bcl-2 overexpressing lymphoid malignancy Radiother Oncol 80 214 222 16916556 10.1016/j.radonc.2006.07.030 1:CAS:528:DC%2BD28Xptlyks70%3D (Pubitemid 44301543)
31. M Jo TH Kim DW Seol JE Esplen K Dorko TR Billiar SC Strom 2000 Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand Nat Med 6 564 567 10802713 10.1038/75045 1:CAS:528:DC%2BD3cXjtFyhtrk%3D (Pubitemid 30305907)
32. SJ Zheng P Wang G Tsabary YH Chen 2004 Critical roles of TRAIL in hepatic cell death and hepatic inflammation J Clin Invest 113 58 64 14702109 1:CAS:528:DC%2BD2cXjsVGmuw%3D%3D
33. K Shudo K Kinoshita R Imamura H Fan K Hasumoto M Tanaka S Nagata T Suda 2001 The membrane-bound but not the soluble form of human Fas ligand is responsible for its inflammatory activity Eur J Immunol 31 2504 2511 11500835 10.1002/1521-4141(200108)31:8<2504::AID-IMMU2504>3.0.CO;2-C 1:CAS:528:DC%2BD3MXmt1entr4%3D (Pubitemid 32785370)
34. T Suda H Hashimoto M Tanaka T Ochi S Nagata 1997 Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing J Exp Med 186 2045 2050 9396774 10.1084/jem.186.12.2045 1:CAS:528:DyaK2sXotVGhsLs%3D (Pubitemid 28013689)
35. T Brunner C Wasem R Torgler I Cima S Jakob N Corazza 2003 Fas (CD95/Apo-1) ligand regulation in T cell homeostasis, cell-mediated cytotoxicity and immune pathology Semin Immunol 15 167 176 14563115 10.1016/S1044-5323(03) 00035-6 1:CAS:528:DC%2BD3sXmsl2rtLc%3D (Pubitemid 38155823)
36. MM Kavurma MR Bennett 2008 Expression, regulation and function of trail in atherosclerosis Biochem Pharmacol 75 1441 1450 18061141 10.1016/j.bcp.2007. 10.020 1:CAS:528:DC%2BD1cXlt1Wjurs%3D (Pubitemid 351375180)
37. MM Kavurma LM Khachigian 2003 Signaling and transcriptional control of Fas ligand gene expression Cell Death Differ 10 36 44 12655294 10.1038/sj.cdd.4401179 1:CAS:528:DC%2BD3sXit12mu78%3D (Pubitemid 36511831)
38. H Liu P Sidiropoulos G Song LJ Pagliari MJ Birrer B Stein J Anrather RM Pope 2000 TNF-alpha gene expression in macrophages: regulation by NF-kappa B is independent of c-Jun or C/EBP beta J Immunol 164 4277 4285 10754326 1:CAS:528:DC%2BD3cXis1WksL8%3D
39. TS Griffith T Brunner SM Fletcher DR Green TA Ferguson 1995 Fas ligand-induced apoptosis as a mechanism of immune privilege Science 270 1189 1192 7502042 10.1126/science.270.5239.1189 1:CAS:528:DyaK2MXpsVyktLs%3D
40. SW Kauma TF Huff N Hayes A Nilkaeo 1999 Placental Fas ligand expression is a mechanism for maternal immune tolerance to the fetus J Clin Endocrinol Metab 84 2188 2194 10372730 10.1210/jc.84.6.2188 1:CAS:528:DyaK1MXjs1Ohsbc%3D
41. J O'Connell MW Bennett GC O'Sullivan J O'Callaghan JK Collins F Shanahan 1999 Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege Clin Diagn Lab Immunol 6 457 463 10391843
42. J O'Connell GC O'Sullivan JK Collins F Shanahan 1996 The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand J Exp Med 184 1075 1082 9064324 10.1084/jem.184.3.1075
43. L Xerri E Devilard J Hassoun C Mawas F Birg 1997 Fas ligand is not only expressed in immune privileged human organs but is also coexpressed with Fas in various epithelial tissues Mol Pathol 50 87 91 9231156 10.1136/mp.50.2.87 1:STN:280:DyaK2sznsVOjtQ%3D%3D
44. EJ Blott G Bossi R Clark M Zvelebil GM Griffiths 2001 Fas ligand is targeted to secretory lysosomes via a proline-rich domain in its cytoplasmic tail J Cell Sci 114 2405 2416 11559749 1:CAS:528:DC%2BD3MXlsFamtL0%3D
45. G Bossi GM Griffiths 1999 Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells Nat Med 5 90 96 9883845 10.1038/4779 1:CAS:528:DyaK1MXmtFOhsw%3D%3D (Pubitemid 29051004)
46. J Qian W Chen M Lettau G Podda M Zornig D Kabelitz O Janssen 2006 Regulation of FasL expression: a SH3 domain containing protein family involved in the lysosomal association of FasL Cell Signal 18 1327 1337 16318909 10.1016/j.cellsig.2005.10.015 1:CAS:528:DC%2BD28Xks1Wjtbk%3D (Pubitemid 44275218)
47. AH Montel MR Bochan JA Hobbs DH Lynch Z Brahmi 1995 Fas involvement in cytotoxicity mediated by human NK cells Cell Immunol 166 236 246 7497525 10.1006/cimm.1995.9974 1:CAS:528:DyaK2MXpvVOktbw%3D (Pubitemid 26014792)
48. T Suda T Okazaki Y Naito T Yokota N Arai S Ozaki K Nakao S Nagata 1995 Expression of the Fas ligand in cells of T cell lineage J Immunol 154 3806 3813 7706720 1:CAS:528:DyaK2MXkvFOrtL4%3D
49. JS He HL Ostergaard 2007 CTLs contain and use intracellular stores of FasL distinct from cytolytic granules J Immunol 179 2339 2348 17675495 1:CAS:528:DC%2BD2sXosVyqs7o%3D
50. WL Hanna JM Turbov HL Jackman F Tan CJ Froelich 1994 Dominant chymotrypsin-like esterase activity in human lymphocyte granules is mediated by the serine carboxypeptidase called cathepsin A-like protective protein J Immunol 153 4663 4672 7963538 1:CAS:528:DyaK2MXit1eqsbk%3D
51. M Lettau H Schmidt D Kabelitz O Janssen 2007 Secretory lysosomes and their cargo in T and NK cells Immunol Lett 108 10 19 17097742 10.1016/j.imlet.2006.10.001 1:CAS:528:DC%2BD2sXhtF2quw%3D%3D (Pubitemid 44970493)
52. DE Jenne J Tschopp 1988 Granzymes, a family of serine proteases released from granules of cytolytic T lymphocytes upon T cell receptor stimulation Immunol Rev 103 53 71 3292396 10.1111/j.1600-065X.1988.tb00749.x 1:CAS:528:DyaL1cXlt1Kqsr8%3D
53. PJ Peters J Borst V Oorschot M Fukuda O Krahenbuhl J Tschopp JW Slot HJ Geuze 1991 Cytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes J Exp Med 173 1099 1109 2022921 10.1084/jem.173.5. 1099 1:CAS:528:DyaK3MXhvVeks7s%3D
54. N Puri PA Roche 2008 Mast cells possess distinct secretory granule subsets whose exocytosis is regulated by different SNARE isoforms Proc Natl Acad Sci USA 105 2580 2585 18250339 10.1073/pnas.0707854105 (Pubitemid 351520556)
55. G Bossi GM Griffiths 2005 CTL secretory lysosomes: biogenesis and secretion of a harmful organelle Semin Immunol 17 87 94 15582491 10.1016/j.smim.2004.09.007 1:CAS:528:DC%2BD2cXhtVCls7vF (Pubitemid 39575984)
56. Y Kojima A Kawasaki-Koyanagi N Sueyoshi A Kanai H Yagita K Okumura 2002 Localization of Fas ligand in cytoplasmic granules of CD8+ cytotoxic T lymphocytes and natural killer cells: participation of Fas ligand in granule exocytosis model of cytotoxicity Biochem Biophys Res Commun 296 328 336 12163021 10.1016/S0006-291X(02)00841-0 1:CAS:528:DC%2BD38XlvF2gsLw%3D
57. D Kassahn U Nachbur S Conus O Micheau P Schneider HU Simon T Brunner 2009 Distinct requirements for activation-induced cell surface expression of preformed Fas/CD95 ligand and cytolytic granule markers in T cells Cell Death Differ 16 115 124 19079288 10.1038/cdd.2008.133 1:CAS:528:DC%2BD1cXhsV2it7zO
58. H Schmidt C Gelhaus R Lucius M Nebendahl M Leippe O Janssen 2009 Enrichment and analysis of secretory lysosomes from lymphocyte populations BMC Immunol 10 41 19640298 10.1186/1471-2172-10-41 1:CAS:528:DC%2BD1MXhtVShtb7O
59. L Pond LA Kuhn L Teyton MP Schutze JA Tainer MR Jackson PA Peterson 1995 A role for acidic residues in di-leucine motif-based targeting to the endocytic pathway J Biol Chem 270 19989 19997 7650016 10.1074/jbc.270.34.19989 1:CAS:528:DyaK2MXnvVClsr0%3D
60. IS Trowbridge JF Collawn CR Hopkins 1993 Signal-dependent membrane protein trafficking in the endocytic pathway Annu Rev Cell Biol 9 129 161 8280459 10.1146/annurev.cb.09.110193.001021 1:CAS:528:DyaK2cXltlKj
61. U Nachbur D Kassahn S Yousefi DF Legler T Brunner 2006 Posttranscriptional regulation of Fas (CD95) ligand killing activity by lipid rafts Blood 107 2790 2796 16332972 10.1182/blood-2005-07-2744 1:CAS:528:DC%2BD28XjtlKlu7Y%3D
62. A Linkermann C Gelhaus M Lettau J Qian D Kabelitz O Janssen 2009 Identification of interaction partners for individual SH3 domains of Fas ligand associated members of the PCH protein family in T lymphocytes Biochim Biophys Acta 1794 168 176 19041431 1:CAS:528:DC%2BD1MXktlChsA%3D%3D
63. M Voss M Lettau O Janssen 2009 Identification of SH3 domain interaction partners of human FasL (CD178) by phage display screening BMC Immunol 10 53 19807924 10.1186/1471-2172-10-53 1:CAS:528:DC%2BD1MXht1yhtb3J
64. J Wenzel R Sanzenbacher M Ghadimi M Lewitzky Q Zhou DR Kaplan D Kabelitz SM Feller O Janssen 2001 Multiple interactions of the cytosolic polyproline region of the CD95 ligand: hints for the reverse signal transduction capacity of a death factor FEBS Lett 509 255 262 11741599 10.1016/S0014-5793(01)03174-X 1:CAS:528:DC%2BD3MXovF2hsrw%3D (Pubitemid 34015953)
65. MP Ghadimi R Sanzenbacher B Thiede J Wenzel Q Jing M Plomann A Borkhardt D Kabelitz O Janssen 2002 Identification of interaction partners of the cytosolic polyproline region of CD95 ligand (CD178) FEBS Lett 519 50 58 12023017 10.1016/S0014-5793(02)02709-6 1:CAS:528:DC%2BD38XjvVSntbw%3D (Pubitemid 34521991)
66. M Hane B Lowin M Peitsch K Becker J Tschopp 1995 Interaction of peptides derived from the Fas ligand with the Fyn-SH3 domain FEBS Lett 373 265 268 7589480 10.1016/0014-5793(95)01051-F 1:CAS:528:DyaK2MXovVygu7w%3D
67. M Lettau J Qian A Linkermann M Latreille L Larose D Kabelitz O Janssen 2006 The adaptor protein Nck interacts with Fas ligand: Guiding the death factor to the cytotoxic immunological synapse Proc Natl Acad Sci USA 103 5911 5916 16595635 10.1073/pnas.0508562103 1:CAS:528:DC%2BD28XktFaitLw%3D
68. W Baum V Kirkin SB Fernandez R Pick M Lettau O Janssen M Zornig 2005 Binding of the intracellular Fas ligand (FasL) domain to the adaptor protein PSTPIP results in a cytoplasmic localization of FasL J Biol Chem 280 40012 40024 16204241 10.1074/jbc.M502222200 1:CAS:528:DC%2BD2MXht1Gjs7%2FF (Pubitemid 41779135)
69. E Zuccato EJ Blott O Holt S Sigismund M Shaw G Bossi GM Griffiths 2007 Sorting of Fas ligand to secretory lysosomes is regulated by mono-ubiquitylation and phosphorylation J Cell Sci 120 191 199 17164290 10.1242/jcs.03315 1:CAS:528:DC%2BD2sXht1Gmtr4%3D (Pubitemid 46206661)
70. PB Thornhill JB Cohn WL Stanford J Desbarats 2008 The adaptor protein Grb2 regulates cell surface Fas ligand in Schwann cells Biochem Biophys Res Commun 376 341 346 18789888 10.1016/j.bbrc.2008.08.164 1:CAS:528: DC%2BD1cXhtFyqtLnJ
71. MB Olszewski AJ Groot J Dastych EF Knol 2007 TNF trafficking to human mast cell granules: mature chain-dependent endocytosis J Immunol 178 5701 5709 17442953 1:CAS:528:DC%2BD2sXktlWhsr8%3D
72. MB Olszewski D Trzaska EF Knol V Adamczewska J Dastych 2006 Efficient sorting of TNF-alpha to rodent mast cell granules is dependent on N-linked glycosylation Eur J Immunol 36 997 1008 16541468 10.1002/eji.200535323 1:CAS:528:DC%2BD28XktVKktLc%3D
73. WJ Beil GR Login M Aoki LO Lunardi ES Morgan SJ Galli AM Dvorak 1996 Tumor necrosis factor alpha immunoreactivity of rat peritoneal mast cell granules decreases during early secretion induced by compound 48/80: an ultrastructural immunogold morphometric analysis Int Arch Allergy Immunol 109 383 389 8634524 10.1159/000237267 1:CAS:528:DyaK28XisFOqtbk%3D
74. LJ Walsh G Trinchieri HA Waldorf D Whitaker GF Murphy 1991 Human dermal mast cells contain and release tumor necrosis factor alpha, which induces endothelial leukocyte adhesion molecule 1 Proc Natl Acad Sci USA 88 4220 4224 1709737 10.1073/pnas.88.10.4220 1:CAS:528:DyaK3MXkt1OnsbY%3D
75. W Shurety A Merino-Trigo D Brown DA Hume JL Stow 2000 Localization and post-Golgi trafficking of tumor necrosis factor-alpha in macrophages J Interferon Cytokine Res 20 427 438 10805378 10.1089/107999000312379 1:CAS:528:DC%2BD3cXislGrt7Y%3D (Pubitemid 30249571)
76. MA Cassatella V Huber F Calzetti D Margotto N Tamassia G Peri A Mantovani L Rivoltini C Tecchio 2006 Interferon-activated neutrophils store a TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) intracellular pool that is readily mobilizable following exposure to proinflammatory mediators J Leukoc Biol 79 123 132 16244105 10.1189/jlb.0805431 1:CAS:528:DC%2BD28XlvVSqtQ%3D%3D (Pubitemid 43054257)
77. TJ Kemp AT Ludwig JK Earel JM Moore RL Vanoosten B Moses K Leidal WM Nauseef TS Griffith 2005 Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L Blood 106 3474 3482 16037389 10.1182/blood-2005-03-1327 1:CAS:528:DC%2BD2MXht1ehsbzP (Pubitemid 41609183)
78. I Monleon MJ Martinez-Lorenzo L Monteagudo P Lasierra M Taules M Iturralde A Pineiro L Larrad MA Alava J Naval A Anel 2001 Differential secretion of Fas ligand-or APO2 ligand/TNF-related apoptosis-inducing ligand-carrying microvesicles during activation-induced death of human T cells J Immunol 167 6736 6744 11739488 1:CAS:528:DC%2BD3MXptFGit70%3D
79. MP Simons KG Leidal WM Nauseef TS Griffith 2008 TNF-related apoptosis-inducing ligand (TRAIL) is expressed throughout myeloid development, resulting in a broad distribution among neutrophil granules J Leukoc Biol 83 621 629 18063697 10.1189/jlb.0707452 1:CAS:528:DC%2BD1cXjtVaqtL8%3D (Pubitemid 351966872)
80. MP Simons JM Moore TJ Kemp TS Griffith 2007 Identification of the mycobacterial subcomponents involved in the release of tumor necrosis factor-related apoptosis-inducing ligand from human neutrophils Infect Immun 75 1265 1271 17194806 10.1128/IAI.00938-06 1:CAS:528:DC%2BD2sXivV2ht7o%3D (Pubitemid 46385818)
81. K Simons E Ikonen 1997 Functional rafts in cell membranes Nature 387 569 572 9177342 10.1038/42408 1:CAS:528:DyaK2sXktFCitrk%3D (Pubitemid 27248754)
82. H Shogomori DA Brown 2003 Use of detergents to study membrane rafts: the good, the bad, and the ugly Biol Chem 384 1259 1263 14515986 10.1515/BC.2003.139 1:CAS:528:DC%2BD3sXnsFKmt74%3D (Pubitemid 37168692)
83. M Dykstra A Cherukuri HW Sohn SJ Tzeng SK Pierce 2003 Location is everything: lipid rafts and immune cell signaling Annu Rev Immunol 21 457 481 12615889 10.1146/annurev.immunol.21.120601.141021 1:CAS:528:DC%2BD3sXjtF2isrc%3D (Pubitemid 37174538)
84. JE Doan DA Windmiller DW Riches 2004 Differential regulation of TNF-R1 signaling: lipid raft dependency of p42mapk/erk2 activation, but not NF-kappaB activation J Immunol 172 7654 7660 15187147 1:CAS:528:DC%2BD2cXks1ags74%3D
85. DF Legler O Micheau MA Doucey J Tschopp C Bron 2003 Recruitment of TNF receptor 1 to lipid rafts is essential for TNFalpha-mediated NF-kappaB activation Immunity 18 655 664 12753742 10.1016/S1074-7613(03)00092-X 1:CAS:528:DC%2BD3sXktVGjurg%3D (Pubitemid 36588582)
86. N Cahuzac W Baum V Kirkin F Conchonaud L Wawrezinieck D Marguet O Janssen M Zornig AO Hueber 2006 Fas ligand is localized to membrane rafts, where it displays increased cell death-inducing activity Blood 107 2384 2391 16282344 10.1182/blood-2005-07-2883 1:CAS:528:DC%2BD28XisFOjtbo%3D (Pubitemid 43345558)
87. F Henkler E Behrle KM Dennehy A Wicovsky N Peters C Warnke K Pfizenmaier H Wajant 2005 The extracellular domains of FasL and Fas are sufficient for the formation of supramolecular FasL-Fas clusters of high stability J Cell Biol 168 1087 1098 15795317 10.1083/jcb.200501048 1:CAS:528:DC%2BD2MXivVGmsrw%3D
88. C Gajate F Mollinedo 2005 Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy J Biol Chem 280 11641 11647 15659383 10.1074/jbc.M411781200 1:CAS:528:DC%2BD2MXisVyjt7k%3D (Pubitemid 40418478)
89. N Holler A Tardivel M Kovacsovics-Bankowski S Hertig O Gaide F Martinon A Tinel D Deperthes S Calderara T Schulthess J Engel P Schneider J Tschopp 2003 Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex Mol Cell Biol 23 1428 1440 12556501 10.1128/MCB.23.4.1428-1440.2003 1:CAS:528:DC%2BD3sXhtF2js7k%3D (Pubitemid 36177050)
90. A Eramo M Sargiacomo L Ricci-Vitiani M Todaro G Stassi CG Messina I Parolini F Lotti G Sette C Peschle R De Maria 2004 CD95 death-inducing signaling complex formation and internalization occur in lipid rafts of type I and type II cells Eur J Immunol 34 1930 1940 15214041 10.1002/eji.200324786 1:CAS:528:DC%2BD2cXlslegu7g%3D (Pubitemid 39256074)
91. P Legembre S Daburon P Moreau JF Moreau JL Taupin 2006 Modulation of Fas-mediated apoptosis by lipid rafts in T lymphocytes J Immunol 176 716 720 16393952 1:CAS:528:DC%2BD28Xht1Crtg%3D%3D
92. JR Muppidi RM Siegel 2004 Ligand-independent redistribution of Fas (CD95) into lipid rafts mediates clonotypic T cell death Nat Immunol 5 182 189 14745445 10.1038/ni1024 1:CAS:528:DC%2BD2cXntFWntg%3D%3D (Pubitemid 38208360)
93. I Treede A Braun P Jeliaskova T Giese J Fullekrug G Griffiths W Stremmel R Ehehalt 2009 TNF-alpha-induced up-regulation of pro-inflammatory cytokines is reduced by phosphatidylcholine in intestinal epithelial cells BMC Gastroenterol 9 53 19594939 10.1186/1471-230X-9-53 1:CAS:528:DC%2BD1MXovVSkurs%3D
94. Rossin A, Derouet M, Abdel-Sater F, Hueber AO (2009) Palmitoylation of the TRAIL receptor DR4 confers an efficient TRAIL-induced cell death signalling. Biochem J 419: 185-92, (2 p following 192)
95. K Chakrabandhu Z Herincs S Huault B Dost L Peng F Conchonaud D Marguet HT He AO Hueber 2007 Palmitoylation is required for efficient Fas cell death signaling EMBO J 26 209 220 17159908 10.1038/sj.emboj.7601456 1:CAS:528:DC%2BD2sXivFOksg%3D%3D (Pubitemid 46094712)
96. H Higuchi T Yamashita H Yoshikawa M Tohyama 2003 PKA phosphorylates the p75 receptor and regulates its localization to lipid rafts EMBO J 22 1790 1800 12682012 10.1093/emboj/cdg177 1:CAS:528:DC%2BD3sXivFCjtb4%3D (Pubitemid 36460136)
97. C Neumann-Giesen B Falkenbach P Beicht S Claasen G Luers CA Stuermer V Herzog R Tikkanen 2004 Membrane and raft association of reggie-1/flotillin-2: role of myristoylation, palmitoylation and oligomerization and induction of filopodia by overexpression Biochem J 378 509 518 14599293 10.1042/BJ20031100 1:CAS:528:DC%2BD2cXisVajsbc%3D (Pubitemid 38367240)
98. M Tanaka T Itai M Adachi S Nagata 1998 Downregulation of Fas ligand by shedding Nat Med 4 31 36 9427603 10.1038/nm0198-031 1:CAS:528: DyaK1cXjt1ahug%3D%3D (Pubitemid 28133076)
99. G Matute-Bello RK Winn M Jonas EY Chi TR Martin WC Liles 2001 Fas (CD95) induces alveolar epithelial cell apoptosis in vivo: implications for acute pulmonary inflammation Am J Pathol 158 153 161 11141488 1:CAS:528: DC%2BD3MXmsFKqsg%3D%3D
100. KL Serrao JD Fortenberry ML Owens FL Harris LA Brown 2001 Neutrophils induce apoptosis of lung epithelial cells via release of soluble Fas ligand Am J Physiol Lung Cell Mol Physiol 280 L298 L305 11159009 1:CAS:528: DC%2BD3MXjtVajt78%3D
101. E Song J Chen N Ouyang F Su M Wang U Heemann 2001 Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer Br J Cancer 85 1047 1054 11592778 10.1054/bjoc.2001.2042 1:CAS:528:DC%2BD3MXot1Sktbk%3D
102. LA O'Reilly L Tai L Lee EA Kruse S Grabow WD Fairlie NM Haynes DM Tarlinton JG Zhang GT Belz MJ Smyth P Bouillet L Robb A Strasser 2009 Membrane-bound Fas ligand only is essential for Fas-induced apoptosis Nature 461 659 663 10.1038/nature08402 1:CAS:528:DC%2BD1MXht1Sqtr7F
103. M Schulte K Reiss M Lettau T Maretzky A Ludwig D Hartmann B de Strooper O Janssen P Saftig 2007 ADAM10 regulates FasL cell surface expression and modulates FasL-induced cytotoxicity and activation-induced cell death Cell Death Differ 14 1040 1049 17290285 1:CAS:528:DC%2BD2sXktlOit7Y%3D
104. PG Knox AE Milner NK Green AG Eliopoulos LS Young 2003 Inhibition of metalloproteinase cleavage enhances the cytotoxicity of Fas ligand J Immunol 170 677 685 12517928 1:CAS:528:DC%2BD3sXktlGhuw%3D%3D
105. M Kriegler C Perez K DeFay I Albert SD Lu 1988 A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF Cell 53 45 53 3349526 10.1016/0092-8674(88) 90486-2 1:CAS:528:DyaL1cXhvVCqu78%3D
106. C Perez I Albert K DeFay N Zachariades L Gooding M Kriegler 1990 A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact Cell 63 251 258 2208285 10.1016/0092-8674(90)90158-B 1:CAS:528:DyaK3cXmtV2kt7s%3D (Pubitemid 20355446)
107. C Borsotti AR Franklin SX Lu TD Kim OM Smith D Suh CG King A Chow C Liu O Alpdogan MR van den Brink 2007 Absence of donor T-cell-derived soluble TNF decreases graft-versus-host disease without impairing graft-versus-tumor activity Blood 110 783 786 17395784 10.1182/blood-2006-10-054510 1:CAS:528:DC%2BD2sXot1emtLg%3D (Pubitemid 47105418)
108. S Muller S Rihs JM Dayer Schneider BE Paredes I Seibold T Brunner C Mueller 2009 Soluble TNF-alpha but not transmembrane TNF-alpha sensitizes T cells for enhanced activation-induced cell death Eur J Immunol 39 3171 3180 10.1002/eji.200939554 19681056 10.1002/eji.200939554 1:CAS:528: DC%2BD1MXhsFWhtbbL
109. P Vassalli 1992 The pathophysiology of tumor necrosis factors Annu Rev Immunol 10 411 452 1590993 10.1146/annurev.iy.10.040192.002211 1:CAS:528:DyaK38XltV2ntLg%3D
110. C Mueller N Corazza S Trachsel-Loseth HP Eugster M Buhler-Jungo T Brunner MA Imboden 1999 Noncleavable transmembrane mouse tumor necrosis factor-alpha (TNFalpha) mediates effects distinct from those of wild-type TNFalpha in vitro and in vivo J Biol Chem 274 38112 38118 10608881 10.1074/jbc.274.53.38112 1:CAS:528:DC%2BD3cXkt1Gkuw%3D%3D (Pubitemid 30026882)
111. KM Mohler PR Sleath JN Fitzner DP Cerretti M Alderson SS Kerwar DS Torrance C Otten-Evans T Greenstreet K Weerawarna SR Kronheim M Petersen M Gerhart CJ Koslosky CJ March RA Black 1994 Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing Nature 370 218 220 8028669 10.1038/370218a0 1:CAS:528:DyaK2cXmsVKitbg%3D (Pubitemid 24236777)
112. RA Black CT Rauch CJ Kozlosky JJ Peschon JL Slack MF Wolfson BJ Castner KL Stocking P Reddy S Srinivasan N Nelson N Boiani KA Schooley M Gerhart R Davis JN Fitzner RS Johnson RJ Paxton CJ March DP Cerretti 1997 A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells Nature 385 729 733 9034190 10.1038/385729a0 1:CAS:528:DyaK2sXhsVGktLs%3D (Pubitemid 27098094)
113. P Reddy JL Slack R Davis DP Cerretti CJ Kozlosky RA Blanton D Shows JJ Peschon RA Black 2000 Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme J Biol Chem 275 14608 14614 10799547 10.1074/jbc.275.19.14608 1:CAS:528:DC%2BD3cXjt1Cnt78%3D (Pubitemid 30339751)
114. T Itai M Tanaka S Nagata 2001 Processing of tumor necrosis factor by the membrane-bound TNF-alpha-converting enzyme, but not its truncated soluble form Eur J Biochem 268 2074 2082 11277930 10.1046/j.1432-1327.2001.02085.x 1:CAS:528:DC%2BD3MXivVars7k%3D (Pubitemid 32852949)
115. Y Zheng P Saftig D Hartmann C Blobel 2004 Evaluation of the contribution of different ADAMs to tumor necrosis factor alpha (TNFalpha) shedding and of the function of the TNFalpha ectodomain in ensuring selective stimulated shedding by the TNFalpha convertase (TACE/ADAM17) J Biol Chem 279 42898 42906 15292243 10.1074/jbc.M403193200 1:CAS:528:DC%2BD2cXotVOgtrY%3D (Pubitemid 39372180)
116. TP Condon S Flournoy GJ Sawyer BF Baker TK Kishimoto CF Bennett 2001 ADAM17 but not ADAM10 mediates tumor necrosis factor-alpha and L-selectin shedding from leukocyte membranes Antisense Nucleic Acid Drug Dev 11 107 116 11334139 10.1089/108729001750171353 1:CAS:528:DC%2BD3MXjtFKltbg%3D
117. CA Lunn X Fan B Dalie K Miller PJ Zavodny SK Narula D Lundell 1997 Purification of ADAM 10 from bovine spleen as a TNFalpha convertase FEBS Lett 400 333 335 9009225 10.1016/S0014-5793(96)01410-X 1:CAS:528:DyaK2sXktl2huw%3D%3D (Pubitemid 27039378)
118. MS Rosendahl SC Ko DL Long MT Brewer B Rosenzweig E Hedl L Anderson SM Pyle J Moreland MA Meyers T Kohno D Lyons HS Lichenstein 1997 Identification and characterization of a pro-tumor necrosis factor-alpha-processing enzyme from the ADAM family of zinc metalloproteases J Biol Chem 272 24588 24593 9305925 10.1074/jbc.272.39.24588 1:CAS:528:DyaK2sXmsFamt74%3D (Pubitemid 27418673)
119. R Mezyk-Kopec M Bzowska K Stalinska T Chelmicki M Podkalicki J Jucha K Kowalczyk P Mak J Bereta 2009 Identification of ADAM10 as a major TNF sheddase in ADAM17-deficient fibroblasts Cytokine 46 309 315 19346138 10.1016/j.cyto.2009.03.002 1:CAS:528:DC%2BD1MXmsVCjurk%3D
120. SM Le Gall P Bobe K Reiss K Horiuchi XD Niu D Lundell DR Gibb D Conrad P Saftig CP Blobel 2009 ADAMs 10 and 17 represent differentially regulated components of a general shedding machinery for membrane proteins such as transforming growth factor alpha, L-selectin, and tumor necrosis factor alpha Mol Biol Cell 20 1785 1794 19158376 10.1091/mbc.E08-11-1135 1:CAS:528: DC%2BD1MXlsFygsro%3D
121. D Hartmann B de Strooper L Serneels K Craessaerts A Herreman W Annaert L Umans T Lubke A Lena Illert K von Figura P Saftig 2002 The disintegrin/ metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts Hum Mol Genet 11 2615 2624 12354787 10.1093/hmg/11.21.2615 1:CAS:528:DC%2BD38XnvVemtrs%3D
122. N Mitsiades WH Yu V Poulaki M Tsokos I Stamenkovic 2001 Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity Cancer Res 61 577 581 11212252 1:CAS:528:DC%2BD3MXht1GmsLs%3D
123. WC Powell B Fingleton CL Wilson M Boothby LM Matrisian 1999 The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis Curr Biol 9 1441 1447 10607586 10.1016/S0960-9822(00)80113-X 1:CAS:528:DC%2BD3cXhtFyjsA%3D%3D (Pubitemid 30023478)
124. H Matsuno K Yudoh Y Watanabe F Nakazawa H Aono T Kimura 2001 Stromelysin-1 (MMP-3) in synovial fluid of patients with rheumatoid arthritis has potential to cleave membrane bound Fas ligand J Rheumatol 28 22 28 11196534 1:CAS:528:DC%2BD3MXnvFSisg%3D%3D
125. K Horiuchi S Le Gall M Schulte T Yamaguchi K Reiss G Murphy Y Toyama D Hartmann P Saftig CP Blobel 2007 Substrate selectivity of epidermal growth factor-receptor ligand sheddases and their regulation by phorbol esters and calcium influx Mol Biol Cell 18 176 188 17079736 10.1091/mbc.E06-01-0014 1:CAS:528:DC%2BD2sXmsFynuw%3D%3D (Pubitemid 46066719)
126. Stetler-Stevenson WG (2008) Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal 1:re6
127. A Amour PM Slocombe A Webster M Butler CG Knight BJ Smith PE Stephens C Shelley M Hutton V Knauper AJ Docherty G Murphy 1998 TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3 FEBS Lett 435 39 44 9755855 10.1016/S0014- 5793(98)01031-X 1:CAS:528:DyaK1cXmtlSitb4%3D (Pubitemid 28432011)
128. MH Lee M Rapti G Murphy 2005 Total conversion of tissue inhibitor of metalloproteinase (TIMP) for specific metalloproteinase targeting: fine-tuning TIMP-4 for optimal inhibition of tumor necrosis factor-{alpha}-converting enzyme J Biol Chem 280 15967 15975 15713681 10.1074/jbc.M500897200 1:CAS:528:DC%2BD2MXjtleitrw%3D (Pubitemid 40616720)
129. M Ahonen M Poukkula AH Baker M Kashiwagi H Nagase JE Eriksson VM Kahari 2003 Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors Oncogene 22 2121 2134 12687014 10.1038/sj.onc.1206292 1:CAS:528:DC%2BD3sXislyitbc%3D (Pubitemid 36539562)
130. AH Baker AB Zaltsman SJ George AC Newby 1998 Divergent effects of tissue inhibitor of metalloproteinase-1,-2, or-3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis J Clin Invest 101 1478 1487 9502791 10.1172/JCI1584 1:CAS:528:DyaK1cXitVWjtbc%3D
131. M Bond G Murphy MR Bennett A Amour V Knauper AC Newby AH Baker 2000 Localization of the death domain of tissue inhibitor of metalloproteinase-3 to the N terminus. Metalloproteinase inhibition is associated with proapoptotic activity J Biol Chem 275 41358 41363 11007798 10.1074/jbc.M007929200 1:CAS:528:DC%2BD3MXjsVKhsg%3D%3D (Pubitemid 32054970)
132. G Li R Fridman HR Kim 1999 Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells Cancer Res 59 6267 6275 10626822 1:CAS:528:DC%2BD3cXktFynsQ%3D%3D
133. L Chesler DW Golde N Bersch MD Johnson 1995 Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1 Blood 86 4506 4515 8541540 1:STN:280:DyaK287islOqtw%3D%3D
134. XW Liu ME Taube KK Jung Z Dong YJ Lee S Roshy BF Sloane R Fridman HR Kim 2005 Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1 Cancer Res 65 898 906 15705888 1:CAS:528:DC%2BD2MXhtVWntL0%3D
135. SM Mariani PH Krammer 1998 Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage Eur J Immunol 28 973 982 9541592 10.1002/(SICI)1521-4141(199803)28:03<973::AID-IMMU973>3.0. CO;2-T 1:CAS:528:DyaK1cXhvFGit74%3D (Pubitemid 28116210)
136. G Loo S Lippens M Hahne F Matthijssens W Declercq X Saelens P Vandenabeele 2003 A Bcl-2 transgene expressed in hepatocytes does not protect mice from fulminant liver destruction induced by Fas ligand Cytokine 22 62 70 12849704 10.1016/S1043-4666(03)00111-X 1:CAS:528:DC%2BD3sXkvFGhtrs%3D (Pubitemid 36808763)
137. J Ogasawara R Watanabe-Fukunaga M Adachi A Matsuzawa T Kasugai Y Kitamura N Itoh T Suda S Nagata 1993 Lethal effect of the anti-Fas antibody in mice Nature 364 806 809 7689176 10.1038/364806a0 1:CAS:528:DyaK3sXmt1elurg%3D (Pubitemid 23261761)
138. I Watermann J Gerspach M Lehne J Seufert B Schneider K Pfizenmaier H Wajant 2007 Activation of CD95L fusion protein prodrugs by tumor-associated proteases Cell Death Differ 14 765 774 17053806 10.1038/sj.cdd.4402051 1:CAS:528:DC%2BD2sXjt1Sku78%3D (Pubitemid 46444514)
139. D Kassahn U Nachbur T Brunner 2007 CD95L pro-drug: a novel Swiss Army Knife in cancer therapy? Cell Death Differ 14 393 394 17301839 10.1038/sj.cdd.4402069 1:CAS:528:DC%2BD2sXhslWht7s%3D
140. ML Moss JM White MH Lambert RC Andrews 2001 TACE and other ADAM proteases as targets for drug discovery Drug Discov Today 6 417 426 11301286 10.1016/S1359-6446(01)01738-X 1:CAS:528:DC%2BD3MXisF2nsbg%3D (Pubitemid 32328296)
141. K Glunde I Stasinopoulos 2009 ADAM17: the new face of breast cancer-promoting metalloprotease activity Cancer Biol Ther 8 1055 1057 19430201 10.1158/1535-7163.MCT-08-1046 1:CAS:528:DC%2BD1MXmtlGqsLo%3D
142. K Horiuchi T Kimura T Miyamoto H Takaishi Y Okada Y Toyama CP Blobel 2007 Cutting edge: TNF-alpha-converting enzyme (TACE/ADAM17) inactivation in mouse myeloid cells prevents lethality from endotoxin shock J Immunol 179 2686 2689 17709479 1:CAS:528:DC%2BD2sXpt1Snu70%3D
143. Y Zhang M Hegen J Xu JC Keith Jr G Jin X Du T Cummons BJ Sheppard L Sun Y Zhu VR Rao Q Wang W Xu R Cowling CL Nickerson-Nutter J Gibbons J Skotnicki LL Lin J Levin 2004 Characterization of (2R, 3S)-2-([[4-(2-butynyloxy)phenyl] sulfonyl]amino)-N, 3-dihydroxybutanamide, a potent and selective inhibitor of TNF-alpha converting enzyme Int Immunopharmacol 4 1845 1857 15531300 10.1016/j.intimp.2004.08.003 1:CAS:528:DC%2BD2cXptl2ksrw%3D (Pubitemid 39504825)
144. K Arimura N Arima K Matsushita H Ohtsubo H Fujiwara T Kukita A Ozaki T Hagiwara H Hamada K Yoshino C Tei 2004 Matrix metalloproteinase inhibitor reduces apoptosis induction of bone marrow cells in MDS-RA Eur J Haematol 73 17 24 15182333 10.1111/j.1600-0609.2004.00261.x 1:CAS:528:DC%2BD2cXlvF2qsrw%3D (Pubitemid 38824185)
145. M DiMartino C Wolff W High G Stroup S Hoffman J Laydon JC Lee D Bertolini WA Galloway MJ Crimmin M Davis S Davies 1997 Anti-arthritic activity of hydroxamic acid-based pseudopeptide inhibitors of matrix metalloproteinases and TNF alpha processing Inflamm Res 46 211 215 9243304 10.1007/s000110050175 1:CAS:528:DyaK2sXntFWmtbs%3D (Pubitemid 27313732)
146. AH Drummond P Beckett PD Brown EA Bone AH Davidson WA Galloway AJ Gearing P Huxley D Laber M McCourt M Whittaker LM Wood A Wright 1999 Preclinical and clinical studies of MMP inhibitors in cancer Ann N Y Acad Sci 878 228 235 10415734 10.1111/j.1749-6632.1999.tb07688.x 1:CAS:528:DyaK1MXkslems74%3D (Pubitemid 29353574)
147. Y Morimoto K Nishikawa M Ohashi 1997 KB-R7785, a novel matrix metalloproteinase inhibitor, exerts its antidiabetic effect by inhibiting tumor necrosis factor-alpha production Life Sci 61 795 803 9275009 10.1016/S0024-3205(97)00561-4 1:CAS:528:DyaK2sXkvFeru7k%3D (Pubitemid 27326935)
148. N Togashi N Ura K Higashiura H Murakami K Shimamoto 2002 Effect of TNF-alpha-converting enzyme inhibitor on insulin resistance in fructose-fed rats Hypertension 39 578 580 11882611 10.1161/hy0202.103290 1:CAS:528: DC%2BD38Xhs1Wksr0%3D (Pubitemid 34165186)
149. FH Igney PH Krammer 2005 Tumor counterattack: fact or fiction? Cancer Immunol Immunother 54 1127 1136 15889255 10.1007/s00262-005-0680-7 (Pubitemid 41396816)
150. HT Lau M Yu A Fontana CJ Stoeckert Jr 1996 Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice Science 273 109 112 8658177 10.1126/science.273.5271.109 1:CAS:528:DyaK28XjvFOkt74%3D